3 studies found for:    Study of Adjuvant Ipilimumab Anti-CTLA4
Show Display Options
Rank Status Study
1 Active, not recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
2 Active, not recruiting
Has Results
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab;   Drug: Placebo
3 Terminated A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: Bacillus Calmette-Guérin (BCG) vaccine;   Drug: Ipilimumab

Indicates status has not been verified in more than two years